Earnings Call Summary | UroGen Pharma Ltd(URGN.US) Q1 2024 Earnings Conference
Earnings Call Summary | UroGen Pharma Ltd(URGN.US) Q1 2024 Earnings Conference
The following is a summary of the UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript:
以下是UroGen Pharma Ltd.（URGN）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
UroGen Pharma reported Q1 2024 revenue of $18.8 million, showing a 10% increase than Q1 2023 due to the sale of JELMYTO.
The company's net loss for Q1 was $32.3 million compared to a $30.2 million loss in Q1 2023.
Costs of revenue decreased to $1.7 million in Q1 2024, down from $2.3 million in Q1 2023, driven mainly by non-recurring payments in the previous year.
R&D expenses increased to $15.5 million in Q1 2024, As a result of expenses related to UGN-102 and the initiation of Phase 3 for UGN-103.
As of March 31, 2024, UroGen had about $164.5 million in cash, cash equivalents, and marketable securities, indicating strong financial standing.
2024 forecasted net product revenue from JELMYTO is projected to be in the range of $95 million to $102 million.
UroGen Pharma報告稱，由於出售了JELMYTO，2024年第一季度收入爲1,880萬美元，比2023年第一季度增長了10％。
該公司第一季度的淨虧損爲3,230萬美元，而2023年第一季度的虧損爲3,020萬美元。
收入成本從2023年第一季度的230萬美元降至2024年第一季度的170萬美元，這主要是由上一年的非經常性付款推動的。
由於與 UGN-102 相關的支出以及 UGN-103 第三階段的啓動，研發費用在 2024 年第一季度增加到 1,550 萬美元。
截至2024年3月31日，UroGen擁有約1.645億美元的現金、現金等價物和有價證券，這表明財務狀況良好。
預計2024年來自JELMYTO的淨產品收入將在9500萬美元至1.02億美元之間。
Business Progress:
業務進展：
UroGen expects significant market potential with UGN-102 and has estimated the market size to be over $3 billion.
The company has planned to complete its NDA submission for the ENVISION study by Q3 of 2024 with potential launch by Q1 2025.
It has also made strides developing UGN-103 for Phase 3 trials and plans to begin its development for UGN-104.
The patient enrollment for JELMYTO in Q1 2024 was the highest ever, signaling continued growth.
The company aims to report safety and tolerability data for combination therapy arms evaluating UGN-301 by late 2024.
UroGen is planning to expand its sales team alongside the commencement of multiple treatment and product trials.
The company is strategizing to expedite the commercial launch of UGN-102 by leveraging the existing prescriber network and a slightly larger salesforce.
UroGen預計，UGN-102 具有巨大的市場潛力，並估計市場規模將超過30億美元。
該公司計劃在2024年第三季度之前完成ENVISION研究的保密協議提交，並可能在2025年第一季度之前啓動。
它還在開發用於三期試驗的 UGN-103 方面取得了長足的進步，並計劃開始開發 UGN-104。
2024年第一季度，JELMYTO的患者入院人數創歷史新高，這表明持續增長。
該公司的目標是在 2024 年底之前報告評估 UGN-301 的聯合療法組的安全性和耐受性數據。
UroGen計劃擴大其銷售團隊，同時開始多項治療和產品試驗。
該公司正在制定戰略，通過利用現有的處方網絡和稍大的銷售隊伍，加快 UGN-102 的商業推出。
More details: UroGen Pharma Ltd IR
更多詳情： UroGen 製藥有限公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。